Abstract |
The purpose of this study was to determine if a hepatitis B vaccination schedule initiated with one recombinant DNA vaccine could be completed with another. Forty-eight adults on a hepatitis B vaccination schedule of 0, 1 and 6 months had received their first two doses with Merck Sharpe and Dohme's recombinant DNA (MSD rDNA) vaccine ( Recombivax HB) at its adult dose of 10 micrograms. At month 6, the subjects were randomized to receive SmithKline Beecham's recombinant DNA (SB rDNA) vaccine ( Engerix-B) at its adult dose of 20 micrograms or MSD rDNA vaccine. Just prior to the third dose of SB rDNA or MSD rDNA vaccine, the geometric mean anti-HBs titres (GMT) were 161 and 168 mIU ml-1 for the two groups, respectively. The GMT at month 7 were 4077 and 2654 mIU ml-1 for those who had received SB rDNA or MSD rDNA vaccine, respectively. This study demonstrates that a hepatitis B vaccination schedule initiated with MSD rDNA vaccine can be completed with SB rDNA vaccine.
|
Authors | L M Bush, G I Moonsammy, J A Boscia |
Journal | Vaccine
(Vaccine)
Vol. 9
Issue 11
Pg. 807-9
(Nov 1991)
ISSN: 0264-410X [Print] Netherlands |
PMID | 1836921
(Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Hepatitis B Antibodies
- Hepatitis B Vaccines
- Vaccines, Synthetic
- Viral Hepatitis Vaccines
|
Topics |
- Adult
- Double-Blind Method
- Female
- Hepatitis B
(prevention & control)
- Hepatitis B Antibodies
(biosynthesis)
- Hepatitis B Vaccines
- Humans
- Immunization, Secondary
(methods)
- Male
- Middle Aged
- Time Factors
- Vaccination
(methods)
- Vaccines, Synthetic
(administration & dosage, immunology)
- Viral Hepatitis Vaccines
(administration & dosage, immunology)
|